



Universiteit
Leiden
The Netherlands

Obstetric hemorrhage: improving care by collaborating across borders

Vries, P.L.M. de

Citation

Vries, P. L. M. de. (2026, January 13). *Obstetric hemorrhage: improving care by collaborating across borders*. *Safe Motherhood*. Retrieved from <https://hdl.handle.net/1887/4286791>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4286791>

Note: To cite this publication please use the final published version (if applicable).

Chapter 4

Severe postpartum hemorrhage and the risk of adverse maternal outcome: a comparative analysis of two population-based studies in France and the Netherlands

P.L.M. de Vries, C. Deneux-Tharaux, C. Caram, F. Goffinet, D.D.C.A. Henriquez, A. Seco, J.G. van der Bom, T. van den Akker

Preventive Medicine Reports. 2024; 40(2):102665

Abstract

Objectives: Among women with severe PPH (sPPH) in France and the Netherlands, we compared incidence of adverse maternal outcome (major obstetric hemorrhage (≥ 2.5 L blood loss) and/or hysterectomy and/or mortality) by mode of delivery. Second, we compared use and timing of resuscitation and transfusion management, second-line uterotonics and uterine-sparing interventions (intra-uterine tamponade, compression sutures, vascular ligation, arterial embolization) by mode of delivery.

Methods: Secondary analysis of two population-based studies of women with sPPH in France and the Netherlands. Women were selected by a harmonized definition for sPPH: (total blood loss ≥ 1500 ml) AND (blood transfusion of ≥ 4 units packed red blood cells and/or multicomponent blood transfusion).

Results: Incidence of adverse maternal outcome after vaginal birth was 793/1002, 79.1% in the Netherlands versus 88/214, 41.1% in France and 259/342, 76.2% versus 160/270, 59.3% after cesarean section. Hemostatic agents such as fibrinogen were administered less frequently ($p < 0.001$) in the Netherlands (vaginal birth: 83/1002, 8.3% versus 105/214, 49.5% in France; cesarean: 47/342, 13.7% and 152/270, 55.6%). Second-line uterotonics were started significantly later after PPH-onset in the Netherlands than France (vaginal birth: 46 versus 25 minutes; cesarean: 45 versus 18 minutes). Uterine-sparing interventions were less frequently ($p < 0.001$) applied in the Netherlands after vaginal birth (394/1002, 39.3%, 134/214, 62.6%) and cesarean (133/342, 38.9% and 155/270, 57.4%). All uterine sparing interventions were initiated later after onset of refractory PPH in the Netherlands.

Conclusion: Incidence of adverse maternal outcome was higher among women with sPPH in the Netherlands than France regardless mode of birth. Possible explanatory mechanisms are earlier and more frequent use of second-line uterotonics and uterine-sparing interventions in France compared to the Netherlands.

Introduction

Postpartum hemorrhage (PPH) is one of the leading causes of severe maternal outcomes globally and has recently been on the rise in several high-income countries.(1–3) Between countries of this type, marked variations in maternal outcomes after PPH have been reported.(4,5) These are not likely to be explained by individual patient characteristics, differences in mode of delivery or by different strategies of PPH-prevention and initial PPH-management between high-income countries.(6,7) This raises the question whether differences in clinical management of refractory PPH may be involved. Such differences might be compounded by a lack of robust evidence for the management of severe PPH and differences in clinical guidance between countries.(8)

Peripartum hysterectomy is a last-resort management option in case of severe PPH. Earlier studies reported a PPH-related maternal mortality ratio and peripartum hysterectomy rate nearly 2-fold as high in France as compared to the Netherlands. (4,5,9–11) Yet, more than half of PPH-related maternal deaths in the Netherlands happened in women with the uterus still in place, suggesting important delay in PPH-management.(10) The importance of timely escalation to more invasive management options for PPH has been stressed by several authors.(12–14) However, the optimal timing of interventions between the onset of PPH in relation to the total amount of blood loss or severe maternal outcome has not been well defined.(15)

Inter-country comparisons of pregnancy outcomes have shown to be useful in revealing suboptimal care by scrutinizing the specificities of different national contexts.(8) As clinical practice and maternal outcome of PPH varies substantially between France and the Netherlands, we hypothesized that a comparison of the severe PPH-management strategies between these two countries could contribute to a better understanding of optimal PPH-management and the reported differences in terms of severe maternal outcome.

The primary outcome of this study was to compare the incidence of adverse maternal outcome, defined as a composite of major obstetric hemorrhage (≥ 2.5 L of blood loss and/or hysterectomy and/or mortality) among women suffering equally severe PPH in France and the Netherlands by mode of delivery. Second, we aimed to compare use and timing of resuscitation and transfusion management, second-line uterotonics and uterine-sparing interventions between both countries by mode of delivery.

Methods

Design: secondary analysis of two population-based studies.

Source and study population: For the Netherlands, data were selected from the TeMPOH-1 study, a nationwide retrospective cohort study of women with severe PPH recruited in 61 hospitals in the Netherlands from January 2011 to January 2013. For France, data were extracted from the EpiMOMs study, a population-based prospective study designed specifically to study severe maternal morbidity in six French regions between May 2012 and November 2013 that collected data from 119 public and private maternity units.

A harmonized definition of severe PPH was applied to select from both studies the broadest common study-population (figure S1). We defined severe PPH as: (total blood loss ≥ 1500 ml) and (blood transfusion of ≥ 4 units of packed red blood cells AND/OR multicomponent blood transfusion). A multicomponent blood transfusion was defined as blood transfusion consisting of a combination of red blood cells and fresh frozen plasma and/or platelet concentrates.

From this study population, we selected women with ‘refractory PPH’, which pertained to having severe PPH according to our harmonized definition, and which was refractory to first-line management (uterine massage, exploration of the uterine cavity, assessment of the genital tract and administration of oxytocin).

Data collection

Women in the TeMPOH-1 study were considered eligible for inclusion in the cohort by cross-referencing data from hospitals’ blood transfusion services with local birth registers in participating hospitals. Women in the EpiMOMs study were identified prospectively by caregivers in participating hospitals and validated by a review of birth logbooks and registers, hospital discharge databases, and laboratory records. For both studies, details pertaining to data collection have been described elsewhere.(16,17)

PPH in France and the Netherlands was managed according to the national guidelines applicable at the time in both countries.(18,19) An overview of both guidelines is given in Table S1.

Blood loss measurement in the TeMPOH-1 study was obtained by weighing gauzes, cloths and surgical swabs and by suction canisters or collector bags in EpiMOMs.

Data dictionaries were provided by each country. If a certain variable was not available, we sought to create a new variable as long as it was comparable in both datasets. If the equivalent of a variable could not be identified in one of the two databases, it was excluded or presented with a dash. Variables not matching after mapping due to different coding, were subjected to harmonized coding. Availability and comparability of each respective dataset are presented in Table S2.

From both databases, we abstracted variables regarding patient characteristics, etiology of bleeding, initial PPH-management, resuscitation- and transfusion management, second-line uterotonics, obstetric management and maternal outcome. Adverse maternal outcome was defined as a composite of bleeding $\geq 2.5L$, hysterectomy or mortality. For the subgroup of women with refractory PPH, we assessed the association between time of onset of the first uterine-sparing intervention (one of the following: intra-uterine balloon tamponade, embolization, compression sutures, vascular ligation) and total volume of blood loss. If multiple uterine-sparing interventions were performed, time of onset of the first uterine-sparing intervention in the sequence was considered as timing of intervention. Patient characteristics were assessed for overall birth and per mode of delivery. All other variables were stratified by mode of delivery.

Statistical analyses: Incidence of severe PPH was calculated per 1,000 births and presented with a 95% confidence interval. Data were checked for normal distribution by histograms. Categorical data were presented by frequency and percentage, and continuous variables by median and interquartile range (25th to 75th percentile) and by mean and standard deviation. Statistical testing by Chi-square tests, T-tests, and kruskall Wallis test to test our null-hypothesis that there is no difference between the France and the Netherlands with regard to the assessed variables. Missing data can be consulted in the supporting information. (Table S3) The total volume of blood loss as a function of the timing of the first invasive intervention was displayed in scatterplots. All analyses were conducted using STATA v15.

Ethical approval: The TeMPOH-1 study was approved by the ethics committee of the Leiden University Medical Center on 31 January 2013 (P12.273) and by the institutional review board of each participating hospital. The study was registered in the Netherlands Trial Register (NTR4079). Need to obtain informed consent was waived by the ethics committee. The EpiMOMs study was approved by the appropriate institutional review board, the Commission Nationale de l'Informatique et des Libertés (CNIL, number 912210). Need to obtain informed consent was

waived, according to the French legislation at that time. Women included in the study were informed and did not indicate their opposition to participate.

Results

Patient and hemorrhage characteristics

In Table 1 we describe the patient characteristics of women sustaining severe PPH in France and the Netherlands. As compared to the Netherlands, more women with severe PPH who gave birth vaginally had an assisted birth in France (212/1002, 21.2% versus 62/214, 28.9%) or cesarean (342/1344, 25.5% versus 270/484, 55.8%). In the Netherlands, more women had a history of PPH regardless mode of birth (vaginal birth:144/1002, 25.1% versus 15/214, 12.9%, $p<0.001$ and for cesarean: 41/342, 17.2% versus 12/270, 7.8%, $p<0.001$). In addition, more women in the Netherlands suffered from hypertensive disorders than in France after vaginal birth (96/1002, 9.6% versus 9/214, 4.2%, $p=0.01$ but not after cesarean birth (39/342, 11.4% versus 27/270, 10.1% respectively, $p=0.58$). (Table 1) Main causes of severe PPH were similar among both countries. (Table S4) As published in the TeMpOH-1 study, the incidence of severe PPH according to our harmonized definition in the Netherlands was 5.0 per 1000 livebirths (1344/270,101). This is in comparison to the EpiMOMs study in France, which found an incidence of severe PPH of 2.7 per 1,000 livebirths (488/182,309). (Figure S1, Table 1)

Table 1. Patient and birth characteristics among women with severe PPH for overall births and stratified by mode of birth in France and the Netherlands (2011-2013).

	France	The Netherlands
Population based denominator	182,309	207,101
Number of women with sPPH¹	484	1344
Incidence sPPH per 1000 births	2.7(2.4-2.9)	5.0 (4.7-5.2)

Table 1. (continued)

	Overall births				Vaginal births				Cesarean births					
	France		The Netherlands		France		The Netherlands		France		The Netherlands			
	N = 484		N=1344		N=214		N=1002		N=270		N=342			
				n	(%)	n	(%)	P-value	n	(%)	n	(%)	P-value	
Patient characteristics														
Age (Mean (std)) ²				30.7	(5.1)	31.2	(4.9)	0.15	32.9	(5.5)	33	(5.1)	0,7	
Parity								0.07					0,06	
<i>nulliparity</i>	210	(43.4)	532	(39.6)	97	(45.5)	428	(42.7)		112	(42.4)	104	(30,4)	
<i>multiparous, no previous cesarean section</i>	177	(36.6)	621	(42.2)	95	(44.6)	493	(49.2)		82	(53.2)	128	(53.4)	
<i>multiparous with previous cesarean section</i>	93	(19.2)	191	(14.2)	21	(9.9)	81	(8.11)		72	(46.8)	110	(46.2)	
History of PPH	27	(10.0)	185	(22.7)	15	(12.9)	144	(25.1)	< 0,001	12	(7.8)	41	(17.2)	< 0,001
Multiple pregnancy	58	(12.0)	84	(6.3)	14	(6.5)	46	(4.6)	0.26	44	(16.3)	38	(11.1)	0,06
Hypertensive disorder	36	(7.4)	135	(10.0)	9	(4.2)	96	(9.6)	0,01	27	(10.0)	39	(11.4)	0,58
Macrosomia	75	(15.5)	280	(20.8)	35	(16.4)	213	(21.3)	0,11	38	(14.1)	67	(19.6)	0,07

Table 1. (continued)

	Overall births				Vaginal births				Cesarean births					
	France		The Netherlands		France		The Netherlands		France		The Netherlands			
	N = 484		N=1344		N=214		N=1002		N=270		N=342			
				n	(%)	n	(%)	P-value	n	(%)	n	(%)	P-value	
Characteristics of birth														
Weeks gestational age (IQR ³)	39	(37-41)	39	(38-71)	39	(38-41)	39		0,43	37	(36-68)	37	(35-39)	0,36
Induction of labor	119	(32.3)	474	(39.6)	68	(31.8)	398	(39.7)	0,06	51	(18.9)	76	(38.9)	0,33
Mode of birth									< 0.001					0.15
<i>Spontaneous vaginal birth</i>	152	(31.4)	790	(58.8)	152	(71.0)	790	(78.8)		-		-		
<i>Assisted birth</i>	62	(12.8)	212	(15.8)	62	(28.9)	212	(21.2)		-		-		
<i>Elective cesarean section</i>	118	(24.4)	147	(11.0)	-		-			118	(43.7)	147	(43.0)	
<i>Emergency cesarean section</i>	152	(31.4)	195	(14.5)	-		-			152	(56.2)	195	(57.0)	
Prophylactic uterotonics ⁴	432	(89.3)	1204	(89.6)	198	(92.5)	908	(90.6)	0.38	234	86.6	296	86.6	0.97

¹= severe postpartum hemorrhage. ² = standard deviation ³ = inter quartile range ⁴ = Oxytocin 5 or 10 IU intramuscular or slow IV in both countries

Adverse maternal outcome was significantly more prevalent among women with severe PPH in the Netherlands as compared to women with severe PPH in France regardless mode of birth (vaginal birth: 793/1002, 79.1% and 88/214, 41.1%, $p<0.001$) and cesarean: (259/342, 76.2% versus 160/270, 59.3% respectively, $p<0.001$). (Table 2) Major obstetric hemorrhage was more prevalent among women with severe PPH in the Netherlands as compared to women in France both in case of vaginal birth (792/1002, 79% versus 82/214, 12.2%, $p<0.001$) and cesarean (257/342, 75.6% versus 142/270, 52.6%, $p<0.001$). Peripartum hysterectomy was significantly less frequently performed in the Netherlands than France after vaginal birth (27/1002, 2.7% versus 26/214, 12.2%, $p<0.001$) and cesarean (46/342, 13.5% versus 55/270, 20.4%, $p=0.02$). We do not report any significant differences in terms of maternal mortality. (Table 2) The profile of the women who died from severe PPH in both countries is presented in table S5.

Table 2. Incidence of adverse maternal outcome in women with severe PPH stratified by mode of birth between France and the Netherlands (2011-2013)

	Vaginal birth			Cesarean birth		
	France	The Netherlands	P-value	France	The Netherlands	P-value
	N=214	N=1002		N=270	N=342	
n%	n%	n%	n%			
Total volume blood loss (L) ¹	2(1.6-2.5)	3(2.5-4.0)	< 0.001	2(1.7-3.0)	3(2.5-4.0)	<0.001
Blood loss $\geq 2,5$ L	82(38.3)	792(79.0)	< 0.001	142(52.6)	257(75.6)	< 0.001
Hysterectomy	26(12.2)	27(2.7)	< 0.001	55(20.4)	46(13.5)	0.02
Maternal death	0(0.0)	4(0.4)	0.36	3(1.1)	3(0.9)	0.78
Adverse maternal outcome ²	88(41.1)	793(79.1)	< 0.001	160(59.3)	259(76.2)	< 0.001

L= liters, PPH= postpartum hemorrhage; ¹ given with median and interquartile range, ² composite of total volume of blood loss ≥ 2.5 L, hysterectomy or mortality

Initial PPH-management

We do not report any statistically significant difference in terms of initial PPH-management among women with severe PPH between both countries. After vaginal birth 677/1002, 67.5% of women with severe PPH in the Netherlands received a first-line uterotonics versus 151/214, 71.9%, $p=0.39$ in France and 231/342, 67.5% versus 192/270, 71.1% respectively ($p=0.34$) after cesarean. (Table 3)

Table 3. First-line management of PPH in women with severe PPH stratified by mode of birth between France and the Netherlands (2011-2013)

	Vaginal Birth				Cesarean birth			
	France		The Netherlands		France		The Netherlands	
	N=214		N=1002	P-value	N=270		N=342	P-value
Manual removal placenta	65	(30.4)	328(32.8)	0.50	232	(85.9)	301(88.0)	0.44
Uterine exploration ¹	149	(69.6)	658(65.8)	0.26	30	(11.1)	36(10.5)	0.81
Urinary catheterization	193	(90.1)	932(93.0)	0.15	270	(100)	342(100)	1
Oxytocin infusion ²	151	(71.9)	677(67.5)	0.39	192	(71.1)	231(67.5)	0.34
Time PPH diagnosis – oxytocin infusion ³	5	(0-15)	7 (0-18)	0.42	0	(0-5)	1 (0-7)	0.64

¹ after spontaneous placenta birth; ² In France, Oxytocin 5-10 IU slow IV followed by oxytocin infusion of 5–10 IU/h for 2 h (Max: 40 IU). In the Netherlands: Oxytocin 5 IU slow IV, followed by oxytocin infusion 2.5 IE/4h ;³ In minutes, median (interquartile range) PPH = postpartum hemorrhage.

Use and timing of resuscitation and transfusion management

Table 2 describes resuscitation/transfusion management per country. Fibrinogen was given less frequently in the Netherlands than France regardless mode of birth (vaginal birth: 83/1002, 8.3% versus 105/2014, 49.5%, $p < 0.001$ respectively; cesarean: 47/342, 13.7% and 152/270, 55.6%, $p < 0.001$). Tranexamic acid and rVIIIa were significantly less used after vaginal birth in the Netherlands than France (428/1002, 42.7%, versus 119/214, 55.6%, $p < 0.001$) and (23/1002, 2.3%, versus 6.5%, $p < 0.001$) respectively. Time to transfusion after PPH-onset was similar among countries. (Table 4)

Table 4. Comparing transfusion therapy in women with severe PPH stratified by mode of birth between France and the Netherlands (2011-2013)

	Vaginal birth					Cesarean birth				
	France N=214		The Netherlands N=1002		P-value	France N=270		The Netherlands N=342		P-value
	n	(%)	n	(%)		n	(%)	n	(%)	
Volume replacement therapy	198	(92.5)	960	(95.8)	0.04	250	(92.5)	303	(88.6)	0.07
<i>Crystalloids</i>	19	(9.1)	95	(9.5)		30	(11.1)	27	(7.8)	
<i>Colloids</i>	19	(9.4)	49	(4.9)		4	(1.4)	0	0	
<i>Crystalloids and colloids</i>	158	(74.0)	816	(81.4)		216	(80.0)	276	(80.8)	
Blood transfusion										
Red blood cells	214	(100,0)	1002	(100.0)	1	270	(100.0)	342	(100.0)	1
Number of units ¹	4	(3-7)	4	(3-5)		5	(3-7)	4	(3-6)	
Fresh frozen plasma	196	(92.5)	876	(87.4)	0.04	243	(90.0)	301	(88.9)	0.91
Number of units ¹	2	(2-4)	2	(2-3)		4	(2-6)	2	(2-5)	
Thrombocytes	44	(20.9)	185	(18.5)	0.4	64	(23.7)	110	(32.8)	0.01
Number of units ¹	1	(1-2)	1	(1-2)		1	(1-3)	1	(1-2)	
Hemostatic agents										
Fibrinogen	105	(49.5)	83	(8.3)	< 0.001	150	(55.6)	47	(13.7)	< 0.001
Tranexamic acid	119	(55.6)	428	(42.7)	< 0.001	140	(52.3)	167	(50.1)	0.51
Factor VII	14	(6.5)	23	(2.3)	< 0.001	6	(2.2)	14	(6.5)	0.23
Time between PPH diagnosis and start blood transfusion (median (IQR)) (minutes)	95	(48-159)	95	(60-162)	0.94	73	(26-199)	80	(35-130)	0.35

¹ among those who were transfused, PPH= postpartum hemorrhage, IQR= inter quartile range

Use and timing of second-line uterotonics

Practitioners in both countries primarily applied sulprostone as second-line uterotonic. These were started significantly later after PPH-onset in the Netherlands than France (vaginal birth: 46 versus 25 min, $p<0.001$; cesarean: 45 versus 18 minutes, $p<0.001$). (Table 5)

Use and timing of uterine-sparing interventions

After both vaginal and cesarean birth, patients with severe PPH were significantly ($p<0.001$) less likely to be treated with uterine-sparing interventions in the Netherlands (vaginal birth: 394/1002, 39.3% and cesarean 133/342, 38.9%) versus France (vaginal birth: 134/214, 62.6% and cesarean 155/270, 57.4%). After vaginal birth, 16/1002, 1.6% of women with severe PPH were treated with vascular ligation or compression sutures in the Netherlands versus 30/214, 14.1% in France ($p<0.001$) and 27/342, 7.9% against 107/270, 39.6% after cesarean ($p<0.001$). Intra-uterine balloon tamponade was more commonly used in the Netherlands than France after cesarean (86/342, 25.2% versus 28/270, 10.4%, $p<0.001$). Embolization was less frequently applied in the Netherlands than France after vaginal birth (116/1002, 11.6% versus 46/214, 21.5%, $p<0.001$) but similar in case of cesarean. (Table 5)

Table 5. Comparing second-line therapy and uterine-sparing interventions in women with severe PPH stratified by mode of birth between France and the Netherlands (2011-2013)

	Vaginal birth					Cesarean birth				
	France N=214		The Netherlands N=1002		P- value	France N=270		The Netherlands N=342		P- value
	N	(%)	N	(%)		N	(%)	N	(%)	
Second-line uterotonics										
Administered	187	(87.3)	826	(82,4)	0.03	192	(71.1)	236	(69.0)	0.35
<i>Ergot alkaloids</i>	0	(0.0)	99	(9,9)		0	(0,0)	28	(8.2)	
<i>Sulprostone</i>	178	(83.1)	679	(67,7)		190	(70.3)	221	(64.6)	
<i>Misoprostol</i>	9	(4.2)	408	(40,7)		2	(0.7)	83	(24.2)	
Time PPH diagnosis - second-line uterotonics (median (IQR ²) (minutes)	25	(15-45)	46	(17-90)	< 0.001	18	(8-45)	45	(12-113)	<0.001
Uterine-sparing interventions										
Women with any uterine- sparing intervention	134	(62.6)	394	(39.3)	< 0.001	155	(57.4)	133	(38.9)	<0.001
Multiple uterine-sparing interventions	28	(13.1)	85	(8.4)	0.03	23	(8.5)	37	(10.8)	0.30
Intra uterine tamponade	86	(40.2)	347	(34.6)	0.12	28	(10.4)	86	(25.2)	<0.001
Uterine compression sutures / vascular ligation	30	(14.1)	16	(1.6)	< 0.001	107	(39.6)	27	(7.9)	<0.001
Embolization	46	(21.5)	116	(11.6)	< 0.001	43	(15.9)	57	(16.7)	0.89

¹ postpartum hemorrhage; ² inter quartile range;

Timing of application of the first uterine-sparing intervention was assessed among 1121 women with refractory PPH (severe PPH refractory to first-line management) in the Netherlands versus 422 women in France. (Figure 1) The total volume of blood loss in relation to the time of onset of the first uterine -paring intervention is displayed for all births and stratified by mode of birth in Figure 1a-1c. In the Netherlands, all types of uterine-sparing intervention were initiated significantly later in the course of refractory PPH. (Table 6) In the Netherlands, 101/1121, 9% women received their first uterine-sparing intervention within the first hour after onset of refractory PPH versus 253/422, 60% in France (p<0.001).

Table 6. Comparing median timing between onset of refractory PPH and application of uterine sparing-interventions among women with refractory PPH stratified by mode of birth between France and the Netherlands (2011-2013).

	Vaginal birth			Cesarean birth		
	France N=188 MedianIQR	The Netherlands N=868 MedianIQR	P-value	France N=234 MedianIQR	The Netherlands N=253 MedianIQR	P-value
Time ¹ between diagnosis refractory PPH - intra-uterine tamponade	39 28-115	59 55-220	0.02	45 30-150	95 (54-315)	< 0.001
Time between diagnosis refractory PPH - compression sutures / ligation	107 80-312	291 250-453	< 0.001	36 28-100	250 220-480	< 0.001
Time between diagnosis refractory PPH - embolization	127 113-322	206 180-387	< 0.001	152 115-380	270 199-485	< 0.001

postpartum hemorrhage, ¹ = time in minutes.




Figure 1. Figure 1a-1c: Total blood loss according to timing of the first invasive intervention for PPH in France and the Netherlands. (a) regardless mode of birth (b) for vaginal birth (c) for cesarean birth PPH = postpartum hemorrhage

In total, 41/1121, 3.6% of women in the Netherlands had ≥ 8 liters of blood loss versus zero women in France. The profile of these women is presented in Table S6.

Discussion

We report a higher incidence of adverse maternal outcome among women with severe PPH in the Netherlands as compared to France. Although there was no difference between countries in terms of the number of women with severe PPH receiving second-line uterotonics, we report a statistically significant longer delay before administration of second-line uterotonics in women with severe PPH in the Netherlands as compared to France. A larger proportion of women in France received hemostatic agents such as Fibrinogen. After both vaginal and cesarean birth, patients with severe PPH in France were significantly more likely to be treated with uterine-sparing interventions which were applied in an earlier stage of hemorrhage in France than the Netherlands.

The increased risk of adverse maternal outcome among women suffering severe PPH in the Netherlands as compared to France reported in this study, seems mainly due to the fact that more women suffered major obstetric blood loss in the Netherlands which is confirmed by the increased volumes of total blood loss among women in the Netherlands reported in this study. This could perhaps be explained by a more expectant management in this country once initial management of PPH has failed, such as increased delay before administration of second-line uterotonics and uterine-sparing interventions.(18,20) The consequences of such delay have also been demonstrated in a large Canadian cohort of vaginal deliveries, reporting a higher odds for hypotension and transfusion for every 5-minute additional delay in the administration of a second-line uteronic.(21) The more frequent use of intra-uterine balloon tamponade and the low use of compression sutures and vascular ligation after cesarean in the Netherlands may also have contributed to the differences in adverse maternal outcome since intra-uterine balloon tamponade may take a longer time to stop the bleeding.(22–24) Reported variations cannot be explained by different recommendations since both countries recommend surgical uterine-sparing interventions as a first step after failure of second-line uterotonics in case of cesarean. This stresses the need to investigate whether Dutch recommendations are interpreted differently or whether obstetricians in the Netherlands feel less inclined to perform hemostatic surgery and if so, why. In this context, surgical simulation trainings could be of interest.(25) The implementation of specific PPH-care bundles as recommended by the World Health Organization could improve guideline adherence.(26) Another explanation of the reported variations in terms of

blood loss could be different methods of blood loss quantification applied in both studies. However, studies comparing the methods applied in both cohorts do not report any evidence to consider one method as more accurate over the other method.(27)

We report a higher use of hemostatic agents among women with severe PPH in France. It has been hypothesized that hypofibrinogenemia is a marker of the risk of severe PPH suggesting early supplementation could reduce severity of PPH.(28) However, this hypothesis was not confirmed by recent studies, showing no reduction of blood loss or improved maternal outcomes after early and systematic treatment with fibrinogen. These findings make it unlikely that the differences in terms of fibrinogen use can explain the increased blood loss among women in the Netherlands and emphasize the need for more prospective and randomized trials to define optimal transfusion strategies among obstetric patients.(29)

In contrast with previous data from national obstetric surveillance systems, which reported a hemorrhage related maternal mortality ratio double as high for France as the Netherlands (0.9 (95% CI 0.5-1.3) versus 0.4 per 100,000 livebirths (95% CI 0.0-1.0)), we did not find any significant difference in terms of hemorrhage related maternal mortality in this study.(5,30) This finding could perhaps be explained in two directions: the fact that the Epimoms study was not nationwide, or by an underreporting of maternal deaths in the Dutch national obstetric surveillance system due to the absence of crosslinking, which has previously resulted in underestimation of maternal deaths in the Netherlands.(10,31)

The aforementioned findings could be interpreted as a reason to escalate management sooner rather than late. Also, among the maternal deaths reported in this study we reported marginal use of uterine-sparing interventions. In line with other data, in the Netherlands 4/7 of women died with the uterus still preserved, stressing the importance of timely escalation of management. Nevertheless, our study findings also stress to remain vigilant to the overuse of uterine-sparing interventions. Indeed, 40% of the French women not meeting our inclusion criteria were treated by a uterine-sparing intervention which was initiated almost simultaneously with second-line uterotonics. In line with the high hysterectomy rate reported in this study in France, this may suggest that obstetricians in France escalate very rapidly when it comes to PPH-management, exposing women to the downsides of such escalation. Earlier studies reported a 9-fold increased risk for hysterectomy among women who gave birth by cesarean yet by stratifying our analyses to mode of birth we were able to bring to light that the reported

differences in terms of hysterectomy between both countries cannot be explained by the fact that more women in France gave birth by cesarean.(4)

The reported incidences of severe PPH in France and the Netherlands in this study are difficult to compare with other high-income countries given the heterogeneity of the applied definitions of severe PPH among studies, which are compounded by the lack of a uniform and global definition of severe PPH.(32–35) Perhaps these differences could be explained by the reported variations in terms of mode of birth or by differences in PPH risk-factors such as hypertensive disorders and history of PPH. The higher proportion of women with vaginal birth in the Netherlands may have resulted in increased barriers and delays before escalation to more invasive management. This may also be compounded by several elements pertaining to maternity care in this country. First, the culture in the Netherlands might revolve more around the notion that physiological birth should proceed without unnecessary interventions, a notion strongly present among parturients and practitioners.(36) Second, differences in clinical practices with regards to manual removal of the placenta between France and the Netherlands may contribute to the delay in the Netherlands before proceeding to more invasive interventions. In the Netherlands, women are generally transferred to the operating theatre for general anesthesia for manual removal of the placenta whereas in France this is performed at the labor ward with the epidural that was already in place for labor.(37) (38) The reported differences in terms of mode of delivery among women with severe PPH in both countries cannot be explained by differences in cesarean section rates alone which were 16.6% in the Netherlands versus 20.2% in France during the study-period.^{25,26} They may reflect variations between specific targets in PPH management resulting in increased risk of severe PPH after cesarean in France such as suboptimal postoperative surveillance, as has been suggested by earlier reports from the French national confidential enquiry, or by an increased risk of PPH among women given birth vaginally in the Netherlands due to the specific elements pertaining to maternity care in the Netherlands specified above.

The increased number of women with hypertensive disorders and history of PPH in the Netherlands may warrant a more proactive approach of these women, as has been highlighted by earlier studies.(39,40) Another explanation could be differences in initial management of hemorrhage, leading to more women with severe PPH in the Netherlands. This seems however to be an unlikable explanatory mechanism as we did not report any differences in terms of prophylactic and initial management of hemorrhage.

This study is one of few comparing extensive data on timing of PPH management and maternal outcome in women with equally severe PPH from two countries with comparable resources. Both countries provided detailed information on the timing of interventions, an important determinant of PPH-related maternal outcome. Setting up a randomized controlled trial to test the efficacy of a therapeutic sequence in the treatment of refractory PPH is very challenging; in this context, international comparisons between countries with different management strategies offer a valuable quasi-experimental alternative for generating evidence. Although the EpiMOMs cohort was not nationwide, the large source population had characteristics similar to the national profile.^{10,33} Both databases were collected over comparable time-periods, reducing the probability that differences in outcome are the result of temporal trends in maternal characteristics. Main limitations arise from the fact that clinical practices may have changed since data from both the cohorts were collected. However, guidelines from both countries did not have any major revisions during the study-period besides from the use of intra-uterine balloon tamponade as a bridging step after vaginal birth in the 2014 revision of the French guideline. Although this could have resulted in an underuse of intra-uterine balloon tamponade in France in our study as compared to current practices, we consider the implementation of guidelines as a continuous process making it likely that this tool was already current practice among practitioners in 2012-2013. From the French source population, we excluded 79 women due to missing data on the total quantity of blood loss or blood transfusion. From these women, 24 had an invasive intervention to treat PPH and the fact that these women could not be included in our analyses could potentially have induced a selection bias.

Conclusion

We report a higher incidence of adverse maternal outcome among women with severe PPH in the Netherlands as compared to France. This difference could not be explained by differences in terms of patient characteristics or initial management of PPH but may be explained by the finding that uterine-sparing interventions to treat severe PPH were applied more frequently and earlier after diagnosis of refractory hemorrhage in France than in the Netherlands. It may also be explained by the finding that women with severe PPH in France were more likely to have an operative or cesarean delivery than those in the Netherlands.

References

1. Corbetta-Rastelli CM, Friedman AM, Sobhani NC, Arditì B, Goffman D, Wen T. Postpartum Hemorrhage Trends and Outcomes in the United States, 2000-2019. *Obstet Gynecol.* 2022;113(1):152-61. éd. 1 janv 2023;
2. Reale SC, Easter SR, Xu X, Bateman BT, Farber MK. Trends in Postpartum Hemorrhage in the United States From 2010 to 2014. *Anesth Analg.* 5apr. J.-C.;130(5):e119-22.
3. Givens M, Einerson BD, Allshouse AA, Bruno AM, Hammad I, Debbink MP, et al. Trends in Unplanned Peripartum Hysterectomy in the United States, 2009-2020. *Obstet Gynecol.* 1 mars 2022;139(3):449-51.
4. Kallianidis AF, Maraschini A, Danis J, Colmorn LB, Deneux-Tharaux C, Donati S, et al. Epidemiological analysis of peripartum hysterectomy across nine European countries. *Acta Obstetricia et Gynecologica Scandinavica.* 2020;99(10):1364-73.
5. Diguisto C.; Saucedo M. KA et al. Maternal mortality in eight European countries with enhanced surveillance systems: descriptive population based study. *BMJ.* 2022;379:e070621.
6. Kallianidis AF, Maraschini A, Danis J, Colmorn LB, Deneux-Tharaux C, Donati S, et al. Management of major obstetric hemorrhage prior to peripartum hysterectomy and outcomes across nine European countries. *Acta Obstet Gynecol Scand.* 2021;100(7):1345-54. éd. juill 2021;
7. McCall SJ, Henriquez D, Edwards HM, van den Akker T, Bloemenkamp KWM, van der Bom J, et al. A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies. *PLoS One.* 2021;16(1):e0244933. éd. 2021;
8. de Vries PLM, Deneux-Tharaux C, Baud D, Chen KK, Donati S, Goffinet F, et al. Postpartum haemorrhage in high-resource settings: Variations in clinical management and future research directions based on a comparative study of national guidelines. *Bjog.* 2023;130(5):1345-54. éd. 31 mai 2023;
9. van den Akker T, Brobbel C, Dekkers OM, Bloemenkamp KWM. Prevalence, Indications, Risk Indicators, and Outcomes of Emergency Peripartum Hysterectomy Worldwide: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 12apr. J.-C.;128(6):1281-94.
10. Ramler PI, Beenackers ICM, Bloemenkamp KWM, Van der Bom JG, Braams-Lisman BAM, Cornette MJM, et al. Nationwide confidential enquiries into maternal deaths because of obstetric hemorrhage in the Netherlands between 2006 and 2019. *Acta Obstet Gynecol Scand.* 2022;101(4):450-60. éd. avr 2022;
11. Saucedo M, Deneux-Tharaux C. [Maternal Mortality, Frequency, causes, women's profile and preventability of deaths in France, 2013-2015]. *Gynecol Obstet Fertil Senol.* 2021;49(1):9-26. éd. janv 2021;
12. Henriquez D, Bloemenkamp KWM, van der Bom JG. Management of postpartum hemorrhage: how to improve maternal outcomes? *J Thromb Haemost [Internet].* 2018/06/09 éd. 8 juin 2018; Disponible sur: <https://www.ncbi.nlm.nih.gov/pubmed/29883040>

13. Della Torre M, Kilpatrick SJ, Hibbard JU, Simonson L, Scott S, Koch A, et al. Assessing preventability for obstetric hemorrhage. *Am J Perinatol*. 2011;28(10):753-60.
14. Lepine SJ, Geller SE, Pledger M, Lawton B, MacDonald EJ. Severe maternal morbidity due to obstetric haemorrhage: Potential preventability. *Aust N Z J Obstet Gynaecol*. 2019;60(2):212-7.
15. Howard TF, Grobman WA. The relationship between timing of postpartum hemorrhage interventions and adverse outcomes. *Am J Obstet Gynecol*. 2015;213(2):239.e1-3.
16. Siddiqui A, Azria E, Howell EA, Deneux-Tharaux C, Group ES. Associations between maternal obesity and severe maternal morbidity: Findings from the French EPIMOMS population-based study. *Paediatr Perinat Epidemiol*. 2018/10/18 éd. janv 2019;33(1):7-16.
17. Henriquez DDCA, Gillissen A, Smith SM, Cramer RA, van den Akker T, Zwart JJ, et al. Clinical characteristics of women captured by extending the definition of severe postpartum haemorrhage with « refractoriness to treatment »: a cohort study. *BMC Pregnancy Childbirth*. 2019;19(1):361-361.
18. NVOG richtlijn postpartum hemorrhagie. Available at: <https://www.nvog.nl/wp-content/uploads/2018/02/Hemorrhagia-postpartum-HPP-3.0-14-11-2013.pdf>. 2018.
19. Goffinet F, Mercier F, Teyssier V, Pierre F, Dreyfus M, Mignon A, et al. [Postpartum haemorrhage: recommendations for clinical practice by the CNGOF (December 2004)]. *Gynecol Obstet Fertil*. 2005;33(4):268-74.
20. Sentilhes L, Vayssières C, Deneux-Tharaux C, Aya AG, Bayoumeu F, Bonnet MP, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). *Eur J Obstet Gynecol Reprod Biol*. 2016/01/17 éd. mars 2016;198:12-21.
21. Knoll W, Phelan R, Hopman WM, Ho AMH, Cenkowski M, Mizubuti GB, et al. Retrospective Review of Time to Uterotonic Administration and Maternal Outcomes After Postpartum Hemorrhage. *Journal of Obstetrics and Gynaecology Canada*. 1 mai 2022;44(5):490-5.
22. Liu C, Gao J, Liu J, Wang X, He J, Sun J, et al. Predictors of Failed Intrauterine Balloon Tamponade in the Management of Severe Postpartum Hemorrhage. *Front Med (Lausanne)*. 2021;8:656422.
23. Revert M, Cottenet J, Raynal P, Cibot E, Quantin C, Rozenberg P. Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study. *BJOG*. 2016;124(8):1255-62.
24. Kong CW, To WW. Prognostic factors for the use of intrauterine balloon tamponade in the management of severe postpartum hemorrhage. *Int J Gynaecol Obstet*. 2018;142(1):48-53.
25. Kerbage Y, Debarge V, Lucot JP, Clouqueur E, Rubod C. Simulation training to teach postpartum hemorrhage surgery to residents. *Eur J Obstet Gynecol Reprod Biol*. 2016;201:27-30.

26. WHO recommendations on the assessment of postpartum blood loss and treatment bundles for postpartum haemorrhage. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
27. Diaz V, Abalos E, Carroli G. Methods for blood loss estimation after vaginal birth. *Cochrane Database Syst Rev.* 20180913^e éd. 13 sept 2018;9(9):Cd010980.
28. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. *Br J Anaesth.* 2012/04/12 éd. juin 2012;108(6):984-9.
29. Deleu F, Deneux-Tharaux C, Chiesa-Dubruille C, Seco A, Bonnet MP. Fibrinogen concentrate and maternal outcomes in severe postpartum hemorrhage: A population-based cohort study with a propensity score-matched analysis. *J Clin Anesth.* 20220602^e éd. oct 2022;81:110874.
30. Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumeu F, Corouge J, Le Gouez A, et al. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. *BJOG.* oct 2021;128(11):1814-23.
31. Kallianidis AF, Schutte JM, van Roosmalen J, van den Akker T. Maternal mortality after cesarean section in the Netherlands. *Eur J Obstet Gynecol Reprod Biol.* oct 2018;229:148-52.
32. Prick BW, Auf Altenstadt JF von S, Hukkelhoven CWPM, Bonsel GJ, Steegers EAP, Mol BW, et al. Regional differences in severe postpartum hemorrhage: a nationwide comparative study of 1.6 million deliveries. *BMC Pregnancy Childbirth.* 2015;15:43-43.
33. Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. *Am J Obstet Gynecol.* 20130716^e éd. nov 2013;209(5):449.e1-7.
34. Pettersen S, Falk RS, Vangen S, Nyfløt LT. Exploring trends of severe postpartum haemorrhage: a hospital-based study. *BMC Pregnancy Childbirth.* 19 mai 2023;23(1):363.
35. Borovac-Pinheiro A, Pacagnella RC, Cecatti JG, Miller S, El Ayadi AM, Souza JP, et al. Postpartum hemorrhage: new insights for definition and diagnosis. *Am J Obstet Gynecol.* 20180414^e éd. août 2018;219(2):162-8.
36. Johnson TR, Callister LC, Freeborn DS, Beckstrand RL, Huender K. Dutch women's perceptions of childbirth in the Netherlands. *MCN Am J Matern Child Nurs.* mai 2007;32(3):170-7.
37. Seijmonsbergen-Schermer AE, Zondag DC, Nieuwenhuijze M, Van den Akker T, Verhoeven CJ, Geerts C, et al. Regional variations in childbirth interventions in the Netherlands: a nationwide explorative study. *BMC Pregnancy Childbirth.* 20180601^e éd. 1 juin 2018;18(1):192.
38. Cheung WM, Hawkes A, Ibish S, Weeks AD. The retained placenta: historical and geographical rate variations. *J Obstet Gynaecol.* 2011;31(1):37-42.
39. Schaap TP, van den Akker T, Zwart JJ, van Roosmalen J, Bloemenkamp KWM. A national surveillance approach to monitor incidence of eclampsia: The Netherlands Obstetric Surveillance System. *Acta Obstet Gynecol Scand.* mars 2019;98(3):342-50.
40. Zwart JJ, Richters A, Öry F, de Vries JIP, Bloemenkamp KWM, van Roosmalen J. Eclampsia in the Netherlands. *Obstetrics & Gynecology [Internet].* 2008;112(4). Disponible sur: https://journals.lww.com/greenjournal/fulltext/2008/10000/eclampsia_in_the_netherlands.13.aspx

Supplemental information

Supplemental Table S1. Comparative overview of national guidelines on PPH in France and the Netherlands applicable during the study-period (2011-2013)

	France	The Netherlands
Prophylactic management of PPH		
Prophylactic uterotonics	Oxytocin: 5 or 10 IU IM or slow IV. Cesarean: 5–10 IU slow IV followed by IV infusion not exceeding 10 IU/h.	Oxytocin: 5 IU IM or slow IV. Cesarean/women at increased risk of PPH: 5 IU slow IV followed by IV infusion 10 IU/4h.
Controlled cord traction	Not recommended	Recommended
Early cord clamping	Not recommended	Not recommended
Manual removal of placenta in the absence of bleeding	Between 30 and 60 min after birth	Between 30-60 min after birth; 60 minutes if blood loss < 500ml, vital parameters normal and operating theatre immediately available.
Initial management of PPH		
First-line uterotonic	Oxytocin 5-10 IU slow IV or IM followed by oxytocin infusion 5–10 IU/h for 2 h (Max: 40 IU)	Oxytocin 5 IU slow IV, followed by oxytocin infusion 2.5 IU/4h
Measurement of blood loss	Collector bag	Weigh blood loss
Uterine massage	Recommended	Recommended
Emptying bladder	Recommended	Not specified
Manual uterine exploration	Recommended	Not specified
Second-line uterotonics		
Misoprostol	Not recommended	Not recommended
Injectable prostaglandins	Sulprostone maximum 500 mcg in 500ml/h	Sulprostone 500 mcg / 30 min, maintenance dose 60-120 mcg/h
Oxytocin agonist	Not recommended	Not recommended
Ergot alkaloids	Not recommended	Ergometrine 0.2 mg IV or IM

Supplemental Table S1. (continued)

	France	The Netherlands
Uterine-sparing interventions		
Uterine tamponade	Use left to the clinician's choice after failure of second-line uterotonic and before recourse to surgical or interventional radiology management. Method: intra-uterine balloon tamponade.	Recommended after failure of second-line uterotonics. Method: intra uterine balloon tamponade.
Radiological arterial embolization	Recommended in case of vaginal birth in hemodynamically stable patients after failure of second-line uterotonics.	Recommended in case of vaginal birth after failure of uterine tamponade.
Compression sutures	Recommended in case of vaginal birth in hemodynamically unstable patients after failure of second-line uterotonics. Recommended in case of caesarean after failure of second-line uterotonics. Type: No type is recommended over another.	Recommended in case of cesarean section after failure of second-line uterotonics. Type: B-Lynch.
Vascular ligation	Recommended in case of vaginal birth in hemodynamically unstable patients after failure of second-line uterotonics. Recommended in case of caesarean after failure of second-line uterotonics Type: Uterine artery ligation/ internal iliac artery ligation	Optional but embolization considered as effective. Type: Uterine artery ligation / internal iliac artery ligation
Last resort management		
Hysterectomy	After failure of uterine sparing interventions. Surgical approach in function of surgeon's preference	In case of life-threatening bleeding. Surgical approach not specified.

Supplemental Table S1. (continued)

	France	The Netherlands
	Transfusion management	
Fluid replacement therapy	Crystalloids	Crystalloids
Erythrocyte concentrates	Goal directed transfusion. Maintain hemoglobin concentration ≥ 8 g/dL.	Fixed ratio transfusion. No specific guideline for PPH. Guideline refers to general national transfusion protocol which recommends a ratio from FFP: RBC of 1:2
FFP	Depending on the severity of the haemorrhage or coagulopathy	See above, usually maintaining a ratio from FFP:RBC of 1:2
Thrombocytes	Maintain above $50 \times 10^9/l$	Not specified
Cell Salvage	Not specified	Not specified
rFVIIa	Not recommended, only for an uncontrolled haemorrhage after failure of conventional treatment and after having attempted to correct platelet levels and other haemostasis indicators	Not recommended but may be considered after consultation of specialist in massive haemorrhage
Fibrinogen	Maintain ≥ 2 g/L	Maintain ≥ 2.5 g/L.
Tranexamic acid	Left to clinicians' discretion	Left to clinicians' discretion

PPH = postpartum hemorrhage, IU: international units, IM = intramuscular, IV = intravenous, h= hour, ml= Milliliters, mcg= microgram, mg= milligram, dL= deciliter, l= liter, FFP = fresh frozen plasma, RBC= red blood cells, rFVIIa= recombinant factor VIIa

Supplemental Table S2. Availability and comparability of variables from each respective dataset with women with severe PPH in the Netherlands and France

Desired variable	France (EPIMOMS)	the Netherlands (TeMPOH-1)	Included in analysis	Comment
Age	Yes	Yes	Yes	
Obesity	Yes	Yes	Yes	
Tabagism	Yes	No	No	
History of PPH	Yes	Yes	Yes	
Polyhydramnios	No	No	No	
Hypertensive disorder	No	Yes	Yes	<i>New variable created in Epimoms: hypertensive disorder created as a composite of preeclampsia + HELLP syndrome + chronic hypertension</i>
Multiple pregnancy	Yes	Yes	Yes	
Macrosomia	No	No	No	<i>Birth weight available. Variable macrosomia defined in both databases as birth weight > 4000 gr at birth</i>
<i>Characteristics of birth</i>				
Parity	Yes	Yes	Yes	
Previous caesarean section	Yes	Yes	Yes	
Mode of birth	Yes	Yes	Yes	
Weeks gestational age	Yes	Yes	Yes	
Induction of labor	Yes	Yes	Yes	
Analgesics during labor	No	Yes	No	
Mode of birth	Yes	Yes	Yes	
Infection during labor	No	Yes	No	
Primary cause of the bleed	Yes, see comment	Yes	Yes	<i>We used a hierarchical approach as to maintain one primary cause: abnormal placentation, placenta previa, placental abruption, trauma, other, atony, retained placenta.</i>
<i>Third stage of labor</i>				
Prophylactic oxytocin	Yes	Yes	yes	
Exploration of the genital tract	No	Yes	No	
Manual removal of the placenta	Yes	Yes	yes	
Manual revision of the uterine cavity	Yes	Yes		
Time diagnosis PPH	Yes	Yes	yes	

Supplemental Table S2. (continued)

Desired variable	France (EPIMOMS)	the Netherlands (TeMPOH-1)	Included in analysis	Comment
<i>Transfusion therapy</i>				
Colloid (ml)	Yes	Yes	Yes	
Crystalloid (ml)	Yes	Yes	Yes	
Number of units of RBC	Yes	Yes	Yes	
Fresh Frozen Plasma	Yes	Yes	Yes	
Number of units of fresh frozen plasma	Yes	Yes	Yes	
Platelets	Yes	Yes	Yes	
Number of units of platelets	Yes	Yes	Yes	
Fibrinogen	Yes	Yes	Yes	
Cell Saver	No	No	No	
rFVIIa	Yes	Yes	Yes	
Tranexamic acid	Yes	Yes	Yes	
Timing of first transfusion unit	Yes	Yes	Yes	
Delay first transfusion unit and PPH	No, see comment	No, see comment	Yes	<i>Variable created by subtracting timing first transfusion unit - time diagnosis PPH</i>
<i>Second-line uterotonics</i>				
Ergot alkaloids	Yes	Yes	Yes	
Sulprostone	Yes	Yes	Yes	
Misoprostol	Yes	Yes	Yes	
Timing first second-line uterotonics	Yes	Yes	Yes	
Delay second-line uterotonics and diagnosis PPH	No, see comment	No, see comment	Yes	<i>Variable created by subtracting timing start second-line uterotonics - time diagnosis PPH</i>

Supplemental Table S2. (continued)

Desired variable	France (EPIMOMS)	the Netherlands (TeMPOH-1)	Included in analysis	Comment
<i>Invasive interventions</i>				
Any invasive intervention	No	No	No	<i>Variable created as a composite of (intra-uterine balloon tamponade yes/no, conservative surgery yes/no)</i>
Intra uterine tamponade	Yes	Yes	Yes	
Conservative surgery	<i>No, see comment</i>	Yes	Yes	<i>Created as a variable of B-lynch + vascular ligation</i>
Embolization	Yes	Yes	Yes	
Multiple invasive interventions	Yes	Yes	Yes	
Timing each intervention	Yes	Yes	Yes	
<i>Maternal morbidity</i>				
Total volume blood loss	Yes	Yes	Yes	
Acute kidney failure	No	Yes	No	
Intensive care unit admission	Yes	Yes	No	<i>Not included as criteria for ICU admission varied between countries making it an inappropriate variable to compare between countries</i>
Blood loss $\geq 2.5L$	No	No	No	<i>Variable created by using total quantity of blood loss</i>
Transfusion $\geq 5PC$	No	No	No	<i>Variable created by using total quantity of PC</i>
Hysterectomy	Yes	Yes	No	
Maternal death	Yes	Yes	Yes	
Adverse maternal outcome	<i>No, see comment</i>	<i>No, see comment</i>	Yes	<i>Variable created as a composite of total volume of blood loss $\geq 2.5L$, hysterectomy or mortality</i>

PPH= postpartum hemorrhage, L= liters, PC = packet cells, ICU= intensive care unit, gr= gram, rFVIIa= recombinant factor VIIa

Table S3. Overview of the number of patients with missing values per variable among the included women with severe PPH in the French and the Dutch dataset

Missing values	France	The Netherlands
Parity	5	0
Gestational age at birth	2	6
Hypertensive disorder	1	0
Volume replacement therapy	20	10
FFP	2	0
Thrombocytes	2	3
Tranexamic acid	6	7
rFVIIa	1	3
Second-line uterotonics	7	0
Intra uterine balloon tamponade	4	0
Embolization	12	0
Hysterectomy	12	0

Supplemental Table S4. Primary underlying cause of bleeding in women with severe PPH stratified by mode of birth in France and the Netherlands (2011-2013)

	Vaginal birth				Cesarean birth			
	France N=214		The Netherlands N=1002		France N=270		The Netherlands N=342	
	n	(%)	n	(%)	n	(%)	n	(%)
Atony	167	(78,0)	685	(68)	111	(41,1)	189	(55,3)
Placenta Praevia	1	(0,5)	2	(0,2)	17	(6,3)	17	(5,0)
Abnormally invasive placenta	7	(3,3)	68	(6,8)	30	(11,1)	39	(11,4)
Placenta abruptio	1	(0,5)	10	(1,0)	34	(12,6)	14	(4,1)
Cesarean surgical injury	11	(5,1)	11	(1,1)	59	(21,9)	76	(22,2)
Retained placenta	18	(8,4)	223	(22,3)	1	(0,4)	4	(1,2)
Other ¹	8	(3,7)	3	(0,3)	17	(6,3)	3	(0,9)
Missing	1	(0,5)	0		1	(0,4)	0	

¹ sepsis, diffuse intravascular coagulation, Willebrand disease, vasa praevia, myoma praevia
 France had multiple causes of PPH coded. We used a hierarchical approach as to maintain one primary cause. The hierarchy we defined was: abnormal placentation, placenta praevia, placental abruptio, trauma, other, atony, retained placenta.

Supplemental Table S5. Characteristics of the women who died from severe PPH in France and the Netherlands (2011-2013)

	France N=3	Netherlands N=7
Obesity (BMI > 30 kg/m ²)	1	1
Parity		
<i>Nulliparity</i>	1	3
<i>multiparous without previous cesarean section</i>	1	4
<i>multiparous with previous cesarean section</i>	1	0
History of PPH	0	0
Multiple pregnancy	0	0
Pre-eclampsia or HELLP	1	2
Macrosomia	0	0
Characteristics of birth		
Induction of labour	1	2
Mode of birth		
<i>Spontaneous vaginal birth</i>	0	1
<i>Instrumental delivery</i>	1	3
<i>Elective cesarean section</i>	1	0
<i>Emergency cesarean section</i>	1	3
Characteristics of hemorrhage		
Cause of bleeding		
<i>Atony</i>	2	5
<i>Placenta Praevia</i>	0	0
<i>Abnormally invasive placenta</i>	0	0
<i>Placenta abruption</i>	0	0
<i>Cesarean surgical injury</i>	1	1
<i>Retained placenta</i>	0	1

Supplemental Table S5. (continued)


	France N=3	Netherlands N=7
Maternal outcome		
Median total volume of blood loss (L)	6	12
Hysterectomy	2	3
Second line uterotonics		
<i>Sulprostone applied</i>	3	7
<i>Time PPH diagnosis - second-line uterotonics (median) (minutes)</i>	30 (20-40)	90 (60-130)
Uterine-sparing interventions		
<i>Intra-uterine tamponade</i>	0	3
<i>Embolization</i>	0	1
<i>Uterine compression sutures/ vascular ligation</i>	2	1

PPH= postpartum hemorrhage, L= liters, BMI= body mass index

Supplemental Table S6. Characteristics of women with severe PPH having extreme blood loss (>8L) in the Netherlands (2011-2013)

	N=41
Obesity (BMI > 30 kg/m ²)	Too many missing data
Parity	
<i>Nulliparity</i>	12 (29.2)
<i>multiparous without previous cesarean section</i>	19 (65.5)
<i>multiparous with previous cesarean section</i>	10 (34.4)
History of PPH	1 (3.4)
Multiple pregnancy	5 (12.2)
Pre-eclampsia or HELLP	4 (9.8)
Macrosomia	3 (7.3)
Characteristics of birth	
Induction of labour	12 (29.3)
Mode of birth	11 (26.8)
<i>Spontaneous vaginal birth</i>	9 (21.96)
<i>Instrumental delivery</i>	10 (24.9)
<i>Elective cesarean section</i>	11 (26.8)
<i>Emergency cesarean section</i>	

¹ Women with extreme blood loss were defined as women with ≥ 8 liters of blood loss (n=41), PPH= postpartum hemorrhage, BMI= body mass index, L= liters



Supplemental Figure S1. flowchart patient inclusion according to harmonized definition severe postpartum hemorrhage (PPH)